Get your reservation for our annual Kentucky Derby seminar now! Details Here
A fifty-year pharmacological patch, a billion-dollar lawsuit, a May 22 vote — and the question nobody in North American racing has ever seriously answered.
A fair, unbiased, objective look at the Lasix debate
Mike Repole doesn’t speak in whispers. When he posted his response to the Churchill Downs v. HISA ruling on April 1, 2026, he came loaded: 300 horses, 80 mares, a billion-dollar lawsuit threat, and a declaration that Lasix will not be banned. Period. Full stop. Mike from Queens has entered the chat.
His anger is understandable. His financial exposure is real. And unlike a lot of the noise that passes for racing industry commentary, he is at least naming the ecosystem — same attorneys, same funding, same power structure — that everyone else tiptoes around.
But the Lasix debate deserves something more than a street fight, even a well-intentioned one. It deserves the science. It deserves the international record. And it deserves the one question that the pro-Lasix establishment in North American racing has spent fifty years carefully avoiding:
If Lasix is a medical necessity, how does the rest of the world race without it?
That question does not have a comfortable answer. What follows is an attempt to build one — honestly, from the evidence, without an agenda on either side.
WHAT LASIX ACTUALLY IS — AND WHAT IT IS NOT
Furosemide — marketed as Lasix and Salix — is one of the most widely used diuretics in human medicine. Cardiologists prescribe it for congestive heart failure. Internists use it for hypertension and edema. It is a blunt, powerful instrument: it forces the kidneys into overdrive, stripping the body of fluid and electrolytes on an aggressive timetable.
In horse racing, it was introduced in the 1960s — initially unsanctioned — and the California Horse Racing Board became one of the first commissions to formally approve it in the early 1970s. The stated purpose was to treat Exercise-Induced Pulmonary Hemorrhage, or EIPH — a condition in which the extreme cardiovascular pressures of high-speed racing cause the delicate capillaries in a horse’s lungs to rupture, allowing blood to enter the airways.
EIPH is real. It is not a manufactured crisis. Blood in the tracheobronchial tree is identified by endoscopic examination in 45% to 75% of racehorses, and hemorrhage is detected in greater than 90% of racehorses via bronchoalveolar lavage. The Merck Veterinary Manual describes it as a significant welfare concern. The American College of Veterinary Internal Medicine commissioned a full consensus statement on it in 2015. Nearly all racehorses experience some degree of it in their career.
None of that is disputed. The dispute is about what Lasix actually does about it — and what else it does while it’s doing it.
WHAT THE PEER-REVIEWED LITERATURE SAYS
The Medical Reality: Reduction, Not Cure
The first thing the veterinary literature is clear about: furosemide does not treat or cure EIPH. It reduces EIPH scores — meaning affected horses bleed less severely when given the drug. But the condition is not eliminated. Even with a full therapeutic dose administered four hours before race time, many horses continue to show blood in the trachea on post-race endoscopy.
The American College of Veterinary Internal Medicine’s 2015 consensus statement — the most comprehensive peer review of the subject — found that much of the evidence supporting furosemide’s efficacy was of low to very low quality, with studies frequently lacking adequate statistical power. That is a peer-reviewed consensus from equine medicine’s own establishment, not an animal rights organization with an agenda.
A 2009 randomized, placebo-controlled crossover trial in the Journal of the American Veterinary Medical Association — involving 167 Thoroughbreds and widely considered the highest-quality evidence available — confirmed that horses given furosemide were substantially less likely to develop moderate to severe EIPH than those given a placebo. The odds ratios were significant: horses without furosemide were 3.3 to 4.4 times more likely to develop any EIPH, and 6.9 to 11 times more likely to develop moderate to severe bleeding.
That is the strongest scientific case for the drug. It is a meaningful reduction in severity. The honest version of the pro-Lasix argument starts and ends there, and it is not nothing.
But the same literature also establishes something the industry has been far less eager to publicize.
The Performance Question: Where the Science Gets Uncomfortable
The largest study ever conducted on furosemide’s effect on race performance examined 22,589 horses and found that mean estimated race times were 0.56 to 1.09 seconds faster for horses receiving furosemide compared to those that did not. In a six-furlong race, that translates to roughly three to five and a half lengths. That is not a rounding error. That can be the difference between a maiden and a stakes horse in the same field.
The mechanism is not complicated. Furosemide is a powerful diuretic. Administered four hours before post, it causes a horse to lose 20 to 30 pounds through urination. A lighter horse expends less energy and accumulates less lactic acid running at high speed. The drug lowers pulmonary vascular pressure — which reduces bleeding — while simultaneously reducing body mass and cardiovascular load. Those two effects cannot be cleanly separated.
There is scientific evidence that horses treated with furosemide four hours before racing do perform better, and that this improvement is also related to the weight loss associated with diuresis, according to Dr. Warwick Bayly of Washington State University’s College of Veterinary Medicine — one of the leading researchers on the subject and not someone who could be dismissed as an anti-racing activist.
One of the most direct statements in the literature came from Dr. Rick Arthur, equine medical director for the California Horse Racing Board and Racing Medication and Testing Consortium officer, speaking at the American Association of Equine Practitioners’ 2013 convention:
“The fact of the matter is horses run faster with Lasix, and it’s one of the issues I’m surprised people don’t realize.”
Horses on Lasix are more likely to win or finish in the top three of a race than horses not on the drug. Race records establish this. The literature confirms it. The industry has known it for decades.
The Masking Problem: The Question WADA Would Ask
Step outside the barn for a moment and look at this from the position of the World Anti-Doping Agency, which governs human athletic competition globally. WADA bans furosemide outright — not because it treats anything in the athletic context, but because diuretics cause rapid, measurable weight loss and dilute urine in ways that can interfere with the detection of other prohibited substances.
That dual-use profile — therapeutic on one hand, potentially masking on the other — is precisely why the international racing community has arrived at a different conclusion than North America. The drug creates a testing environment that is measurably harder to police. That is not speculation. It is pharmacology.
The racing industry’s standard response to the masking concern is to note that testing protocols are rigorous and that the drug’s diuretic window is well-understood. That response has merit as far as it goes. What it doesn’t address is the systemic problem: when you administer a drug that confounds testing to 90% of the field on race day, you have fundamentally altered the evidentiary environment for every other substance you are trying to detect.
WHAT THE REST OF THE WORLD DECIDED
This is the part of the conversation that the North American racing establishment has never found a satisfying answer for.
The United Kingdom bans race-day furosemide. Australia bans it. Japan permits it in training but prohibits it on race days. Germany goes furthest of all — banning it in both training and racing, and prohibiting known bleeders from being registered as recognized stallions, cutting off their ability to pass the condition through the breeding shed.
As Dr. Arthur himself acknowledged: “The international racing industry doesn’t use Lasix to race, and their horses are every bit as healthy as ours.”
That sentence deserves to sit on the page without a lot of surrounding commentary. The countries that ban race-day Lasix are not experiencing catastrophic welfare crises. They are not watching their fields bleed out in the starting gate. Their horses race, they retire, the sport continues. The argument that Lasix is an indispensable medical tool collapses against the sustained, documented reality of global racing conducted without it.
Germany’s approach is the most instructive, because it addresses the problem at its source. EIPH has a documented heritable component in Thoroughbreds. Repeated breeding of known bleeders — prioritizing talent and commercial value over respiratory health — has produced a North American population with unusually high EIPH prevalence. Germany recognized this decades ago and acted accordingly, restricting the breeding of affected horses. North America chose the pharmacological patch instead.
Lasix didn’t solve the bleeding problem. It made it profitable to stop caring about it.
THE REPOLE POSITION: HEARD, AND TAKEN SERIOUSLY
Mike Repole’s tweet is the loudest honest voice in this debate right now, and it deserves a fair accounting.
His core argument is not that EIPH doesn’t exist. It is not that Lasix has no side effects. His argument is that after decades of widespread, regulated use, a sudden ban without transition would cause massive economic harm to horsemen who have built their operations around current medication frameworks — and that HISA is attempting to act unilaterally and without legal standing to impose it.
That last part is, in fact, what our coverage of the CDI ruling documented. The court found that HISA acted in an arbitrary and capricious manner on its fee methodology. Repole is extending that legal pattern to the Lasix vote: if the Authority has demonstrated a willingness to exceed its authority in one domain, why would horsemen trust it to get this right?
His financial exposure is also completely real. Three hundred horses and eighty mares represent an operation built on assumptions — veterinary protocols, race schedules, medication windows — that have been in place for decades. A sudden prohibition creates genuine management chaos that falls hardest on the working horsemen at the barn level, not on the institutional power structures debating it in conference rooms.
The trainers who signed the Bloodhorse letter in February — W.I. Mott, Chad Brown, Mark Casse, Jena Antonucci, Ron Moquett, and HBPA CEO Eric Hamelback — made a version of the same argument with more measured language: “Eliminating the medication will not eliminate the condition. It will remove a regulated therapeutic tool currently administered under veterinary oversight and strict protocols.” That is true, as far as it goes.
It just doesn’t go all the way to answering the question that the United Kingdom, Australia, and Japan answered differently.
THE QUESTION NOBODY HAS ANSWERED
Here is where intellectual honesty requires going somewhere uncomfortable, regardless of where you stand on the vote.
If Lasix is primarily a welfare medication, why has North American racing never developed a serious breeding protocol to address the underlying genetic prevalence of EIPH — the way Germany did? Why, after fifty years and hundreds of millions of doses, is the answer still the same syringe every four hours on race day?
If Lasix is medically necessary, why do countries with comparable or superior equine welfare records race successfully without it? What is the Australian or British Thoroughbred getting that the American one isn’t?
If the performance enhancement is incidental and secondary to the welfare benefit, why has North American racing consistently resisted the kind of dose restrictions, pre-race testing windows, or alternative management protocols that would isolate the therapeutic effect from the competitive advantage?
These are not gotcha questions. They are the questions that any serious sport regulator would ask — and has asked, everywhere but here.
The Washington State University study, funded by HISA, is attempting to generate the longitudinal data that should inform the May 22 vote. That is the right approach. Dr. Bayly’s team is tracking approximately 30,000 racehorses across pre-ban and post-ban periods to evaluate career length, EIPH severity, and race participation. That study deserves to be completed and its conclusions deserve to be heard before a vote with industry-wide consequences is taken.
If the data shows meaningful welfare harm from the ban — shorter careers, more severe bleeding episodes, higher breakdown rates — then the industry will have scientific grounds to argue for continued use under tighter protocols. That would be a legitimate outcome.
If the data mirrors what the international record already suggests — that horses race successfully and healthily without race-day furosemide — then North American racing will have to reckon with what these years of near-universal use was actually about.
The Past The Wire TAKE
Mike Repole is not wrong to fight. He is not wrong to name the ecosystem. He is not wrong to demand that HISA operate within its legal authority and that any major policy shift be grounded in evidence rather than optics.
The honest version of this debate is not “Lasix will NOT be banned, period” versus “ban it immediately.” The honest version is a sport looking in the mirror and asking why it spent half a century medicating a structural problem in its breeding population rather than addressing the structural problem.
The answer, as usual, is money. Breeding for speed at all costs produces bleeders. Lasix makes bleeders competitive. Competitive horses generate purses, breeding fees, and wagering handle. The system is internally coherent — and externally indefensible when measured against any serious standard of equine welfare or competitive integrity.
Germany looked at that system and said no. The rest of the world largely followed. North America said yes, and built an industry around it.
That is the conversation May 22 is actually forcing.
The race isn’t between Lasix and HISA. It’s between fifty years of institutional inertia and the sport’s ability to finally ask itself an honest question.
SOURCES & REFERENCES
American College of Veterinary Internal Medicine Consensus Statement on EIPH. Journal of Veterinary Internal Medicine, 2015; 29(3):743–758.
Hinchcliff KW, Morley PS, Guthrie AJ. Efficacy of furosemide for prevention of EIPH in Thoroughbred racehorses. J Am Vet Med Assoc. 2009;235(1):76-82.
Gross DK et al. Effect of furosemide on performance of Thoroughbreds racing in the United States and Canada. J Am Vet Med Assoc. 1999;215:670–675.
Bayly W. Is Furosemide a Necessary Medication for Racehorses? Light Up Racing / Washington State University. 2024.
Arthur RM. Furosemide Debate Continues. AVMA/JAVMA News. February 2014.
Washington State University / HISA-funded longitudinal study: Bayly W, Sanz M. WSU College of Veterinary Medicine. April 2024.
Mott WI, Brown C, Casse M et al. Letters to the Editor: Lasix Exemption Should Continue. BloodHorse. February 2026.
Merck Veterinary Manual: Exercise-Induced Pulmonary Hemorrhage in Horses. Updated September 2024.
Knych HK et al. Effectiveness of furosemide in attenuating EIPH when administered at 4- and 24-hours prior to high speed training. Equine Vet J. 2018;50(3):350-355.
